Cam Gallagher compensation by year
Zentalis Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $485,942 | $593,600 | $537,199 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $3,580,165 | $3,809,826 | $2,568,515 |
| Option awards | $6,281,685 | $3,879,082 | $1,709,841 |
| Non-equity incentive | $280,000 | $296,800 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $1,752 | $1,752 | $1,003,469 |
| Total | $10,629,545 | $8,581,060 | $5,819,024 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zentalis Pharmaceuticals, Inc. DEF 14A filed April 30, 2025, accession 0001725160-25-000092, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Zentalis Pharmaceuticals, Inc. filed document, accession 0001725160-25-000092. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 192,500 | $583,275 | — |
| RSU | 120,819 | $366,082 | — |
| RSU | 55,536 | $168,274 | — |
| RSU | 4,101 | $12,426 | — |
| RSU | 2,187 | $6,627 | — |
| Option | 126,701 | — | $23.65 |
| Option | 118,015 | — | $24.75 |
| Option | 5,614 | — | $52.61 |
| Option | 1,094 | — | $38.76 |
| Option | 152,396 | — | $11.69 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Zentalis Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Zentalis Pharmaceuticals’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Julie Eastland | President and Chief Executive Officer | $8,188,909 |
| Kimberly Blackwell | Former Chief Executive Officer and Interim Chief Medical Officer | $7,466,453 |
| Diana Hausman | Former Chief Medical Officer | $7,063,793 |
| Cam Gallagher · this page | Former President, Interim Chief Financial Officer and Interim Treasurer | $5,819,024 |
| Mark Lackner | Former Chief Scientific Officer | $4,788,822 |
| Andrea Paul | Former Chief Legal Officer and Corporate Secretary | $3,678,975 |
Board service
Zentalis Pharmaceuticals board · FY2021–FY2022| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2022 | — | — | — | — | — |
| FY2021 | $0 | $532,950 | $1,049,579 | $515,177 | $2,097,706 |
Each year as the company reported it in Zentalis Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Zentalis Pharmaceuticals pays directors a $45,000 cash retainer and $500,000 in RSUs. As stated in Zentalis Pharmaceuticals's FY2022 proxy.
The full Zentalis Pharmaceuticals compensation record
free company briefThis page is one person within Zentalis Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Zentalis Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zentalis Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.